View in EDS PDF Full Text

Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial.

Saved in:
Bibliographic Details
Title: Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial.
Authors: Ravandi F; Department of Leukemia, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA. fravandi@mdanderson.org., Roboz GJ; Weill Cornell Medicine, New York, NY, USA.; New York Presbyterian Hospital, New York, NY, USA., Wei AH; Department of Clinical Haematology, The Alfred Hospital, Melbourne, Australia.; Australian Centre for Blood Diseases, Monash University, Melbourne, Australia., Döhner H; Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany., Pocock C; Kent & Canterbury Hospital, Canterbury, UK., Selleslag D; AZ Sint-Jan Brugge-Oostende AV, Bruges, Belgium., Montesinos P; Hospital Universitari i Politècnic La Fe, Valencia, Spain., Sayar H; Indiana University Cancer Center, Indianapolis, IN, USA., Musso M; La Maddalena - Casa di Cura, Palermo, Italy., Figuera-Alvarez A; Hospital Universitario de La Princesa, Madrid, Spain., Safah H; Tulane University Health Science Center, New Orleans, LA, USA., Tse W; University of Louisville School of Medicine, Louisville, KY, USA., Sohn SK; Kyungpook National University Hospital, Daegu, Korea., Hiwase D; Royal Adelaide Hospital, Adelaide, Australia., Chevassut T; Brighton and Sussex Medical School, Brighton, UK., Pierdomenico F; Portuguese Institute of Oncology Lisbon, Lisbon, Portugal., La Torre I; Celgene, a Bristol-Myers Squibb Company, Boudry, Switzerland., Skikne B; University of Kansas Medical Center, Kansas City, KS, USA.; Bristol Myers Squibb, Princeton, NJ, USA., Bailey R; Bristol Myers Squibb, Princeton, NJ, USA., Zhong J; Bristol Myers Squibb, Princeton, NJ, USA., Beach CL; Bristol Myers Squibb, Princeton, NJ, USA., Dombret H; Hôpital Saint-Louis, Assistance Publique - Hôpitaux de Paris (AP-HP), Paris, France.; Institut de Recherche Saint-Louis, Université de Paris, Paris, France.
Source: Journal of hematology & oncology [J Hematol Oncol] 2021 Aug 28; Vol. 14 (1), pp. 133. Date of Electronic Publication: 2021 Aug 28.
Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Biomed Central Country of Publication: England NLM ID: 101468937 Publication Model: Electronic Cited Medium: Internet ISSN: 1756-8722 (Electronic) Linking ISSN: 17568722 NLM ISO Abbreviation: J Hematol Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Links:
  – Type: pdflink
Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 34454540
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Ravandi+F%22">Ravandi F</searchLink>; Department of Leukemia, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA. fravandi@mdanderson.org.<br /><searchLink fieldCode="AU" term="%22Roboz+GJ%22">Roboz GJ</searchLink>; Weill Cornell Medicine, New York, NY, USA.; New York Presbyterian Hospital, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Wei+AH%22">Wei AH</searchLink>; Department of Clinical Haematology, The Alfred Hospital, Melbourne, Australia.; Australian Centre for Blood Diseases, Monash University, Melbourne, Australia.<br /><searchLink fieldCode="AU" term="%22Döhner+H%22">Döhner H</searchLink>; Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany.<br /><searchLink fieldCode="AU" term="%22Pocock+C%22">Pocock C</searchLink>; Kent & Canterbury Hospital, Canterbury, UK.<br /><searchLink fieldCode="AU" term="%22Selleslag+D%22">Selleslag D</searchLink>; AZ Sint-Jan Brugge-Oostende AV, Bruges, Belgium.<br /><searchLink fieldCode="AU" term="%22Montesinos+P%22">Montesinos P</searchLink>; Hospital Universitari i Politècnic La Fe, Valencia, Spain.<br /><searchLink fieldCode="AU" term="%22Sayar+H%22">Sayar H</searchLink>; Indiana University Cancer Center, Indianapolis, IN, USA.<br /><searchLink fieldCode="AU" term="%22Musso+M%22">Musso M</searchLink>; La Maddalena - Casa di Cura, Palermo, Italy.<br /><searchLink fieldCode="AU" term="%22Figuera-Alvarez+A%22">Figuera-Alvarez A</searchLink>; Hospital Universitario de La Princesa, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Safah+H%22">Safah H</searchLink>; Tulane University Health Science Center, New Orleans, LA, USA.<br /><searchLink fieldCode="AU" term="%22Tse+W%22">Tse W</searchLink>; University of Louisville School of Medicine, Louisville, KY, USA.<br /><searchLink fieldCode="AU" term="%22Sohn+SK%22">Sohn SK</searchLink>; Kyungpook National University Hospital, Daegu, Korea.<br /><searchLink fieldCode="AU" term="%22Hiwase+D%22">Hiwase D</searchLink>; Royal Adelaide Hospital, Adelaide, Australia.<br /><searchLink fieldCode="AU" term="%22Chevassut+T%22">Chevassut T</searchLink>; Brighton and Sussex Medical School, Brighton, UK.<br /><searchLink fieldCode="AU" term="%22Pierdomenico+F%22">Pierdomenico F</searchLink>; Portuguese Institute of Oncology Lisbon, Lisbon, Portugal.<br /><searchLink fieldCode="AU" term="%22La+Torre+I%22">La Torre I</searchLink>; Celgene, a Bristol-Myers Squibb Company, Boudry, Switzerland.<br /><searchLink fieldCode="AU" term="%22Skikne+B%22">Skikne B</searchLink>; University of Kansas Medical Center, Kansas City, KS, USA.; Bristol Myers Squibb, Princeton, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Bailey+R%22">Bailey R</searchLink>; Bristol Myers Squibb, Princeton, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Zhong+J%22">Zhong J</searchLink>; Bristol Myers Squibb, Princeton, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Beach+CL%22">Beach CL</searchLink>; Bristol Myers Squibb, Princeton, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Dombret+H%22">Dombret H</searchLink>; Hôpital Saint-Louis, Assistance Publique - Hôpitaux de Paris (AP-HP), Paris, France.; Institut de Recherche Saint-Louis, Université de Paris, Paris, France.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101468937%22">Journal of hematology & oncology</searchLink> [J Hematol Oncol] 2021 Aug 28; Vol. 14 (1), pp. 133. <i>Date of Electronic Publication: </i>2021 Aug 28.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Biomed+Central%22">Biomed Central </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101468937 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1756-8722 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2217568722%22">17568722 </searchLink><i>NLM ISO Abbreviation: </i>J Hematol Oncol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=34454540
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1186/s13045-021-01142-x
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 133
    Titles:
      – TitleFull: Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Ravandi F
      – PersonEntity:
          Name:
            NameFull: Roboz GJ
      – PersonEntity:
          Name:
            NameFull: Wei AH
      – PersonEntity:
          Name:
            NameFull: Döhner H
      – PersonEntity:
          Name:
            NameFull: Pocock C
      – PersonEntity:
          Name:
            NameFull: Selleslag D
      – PersonEntity:
          Name:
            NameFull: Montesinos P
      – PersonEntity:
          Name:
            NameFull: Sayar H
      – PersonEntity:
          Name:
            NameFull: Musso M
      – PersonEntity:
          Name:
            NameFull: Figuera-Alvarez A
      – PersonEntity:
          Name:
            NameFull: Safah H
      – PersonEntity:
          Name:
            NameFull: Tse W
      – PersonEntity:
          Name:
            NameFull: Sohn SK
      – PersonEntity:
          Name:
            NameFull: Hiwase D
      – PersonEntity:
          Name:
            NameFull: Chevassut T
      – PersonEntity:
          Name:
            NameFull: Pierdomenico F
      – PersonEntity:
          Name:
            NameFull: La Torre I
      – PersonEntity:
          Name:
            NameFull: Skikne B
      – PersonEntity:
          Name:
            NameFull: Bailey R
      – PersonEntity:
          Name:
            NameFull: Zhong J
      – PersonEntity:
          Name:
            NameFull: Beach CL
      – PersonEntity:
          Name:
            NameFull: Dombret H
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 28
              M: 08
              Text: 2021 Aug 28
              Type: published
              Y: 2021
          Identifiers:
            – Type: issn-electronic
              Value: 1756-8722
          Numbering:
            – Type: volume
              Value: 14
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Journal of hematology & oncology
              Type: main
ResultId 1